MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from revenue
interest financing...
-$150,000K
Proceeds from
borrowings, net of debt...
$48,901K
Proceeds from sale of
marketable securities
$330,217K
Proceeds from exercises
of options
$2,402K
Proceeds from issuance of
common stock under espp
-$533K
Net cash provided by
financing activities
$194,472K
Net cash provided by
investing activities
$12,437K
Canceled cashflow
$7,364K
Canceled cashflow
$317,780K
Net increase
(decrease) in cash and cash...
$63,174K
Canceled cashflow
$143,735K
Payments of debt issuance
costs
$6,596K
Payments on borrowings
$700K
Payment on revenue
interest financing...
$68K
Stock-based compensation
$27,906K
Accounts payable
$9,012K
Non-cash interest on
revenue interest...
-$5,121K
Accounts receivable
-$4,399K
Depreciation and
amortization
$1,200K
Amortization of debt issuance
costs
$335K
Non-cash lease expense
$281K
Net loss on disposal
of fixed assets
-$30K
Purchases of marketable
securities
$309,515K
Cash paid for
capitalized market approval...
$8,000K
Purchases of property and
equipment
$265K
Net cash used in
operating activities
-$143,694K
Effect of foreign
exchange rate changes on...
-$41K
Canceled cashflow
$48,284K
Net loss
-$168,035K
Contract liabilities
$8,838K
Inventory
$5,710K
Amortization of premium on
marketable securities
$4,096K
Interest receivable on
marketable securities
$1,957K
Prepaid expenses and
other current assets
$1,655K
Other non-current
assets
$701K
Unrealized foreign
currency transaction...
$415K
Change in fair value of
warrant liability
-$315K
Accrued expenses
-$254K
Realized (gain) loss on
marketable securities
$2K
Back
Back
Cash Flow
source: myfinsight.com
Nuvation Bio Inc. (NUVB-WT)
Nuvation Bio Inc. (NUVB-WT)